The proliferative activity of 16 tumour specimens from 13 patients with neuroendocrine tumours of the gastroenteropancreatic endocrine system was studied by DNA flow cytometry and immunohistology for the nuclear Ki67 proliferation antigen. Equivalent results were obtained with both methods, which showed the proliferative activity of gastroenteropancreatic neuroendocrine tumours to be heterogeneous. In Since the growth of gastroenteropancreatic neuroendocrine tumours is not yet understood we studied the proliferative activity of benign and malignant gastroenteropancreatic neuroendocrine tumours using two different approaches.
The biology of neuroendocrine tumours of the gastroenteropancreatic endocrine system' is characterised by autonomous hormone synthesis and secretion that typically result in peculiar hormonal syndromes,2" and by autonomous growth. While several experimental and clinical studies have focused on the autonomous hormone production of these endocrine tumours,4 far less is known about their growth behaviour.
Commensurate with our incomplete knowledge of the biology of these tumours, medical (non-surgical) treatment of gastroenteropancreatic neuroendocrine tumours is at present more effective in controlling the hormonal activity than the autonomous growth of the tumour. Previous attempts at antineoplastic chemotherapy met with mixed success, ' and each patient's response is considered unpredictable. More recent approaches with hormone treatment using the somatostatin analogue octreotide have not yet provided convincing evidence that octreotide is effective in controlling tumour growth,6 and the results of treatment with interferon alfa are also controversial.""
Since the growth of gastroenteropancreatic neuroendocrine tumours is not yet understood we studied the proliferative activity of benign and malignant gastroenteropancreatic neuroendocrine tumours using two different approaches.
Methods A total of 16 tumour specimens (primary tumour and metastases) obtained from 13 tumour localised in the parapancreatic retroperitoneum (patient 5). In the latter case no visceral primary tumour was evident over five years of observation including three laparotomies.
In three patients (4, 6, and 7), both primary tumour and metastases were investigated. In two patients (2 and 8) only metastases were available for this study.
Proliferative activity was assessed first by DNA flow cytometry. " 1 With this method cellular DNA content can be analysed, and cells can be quantified as percentages within the phases G0-/G,-(presynthesis), S-(DNA synthesis), and G,/M-(premitosis and mitosis) of the cell cycle.'3 DNA flow cytometry was performed as described in detail elsewhere. 14 15 Cells were prepared from fresh frozen tumour tissue. DNA content-dependent fluorescence was measured by an ICP 22 cytometer (Phywe, Gottingen, Germany) at 365 nm excitation. Background debris was corrected, as previously reported, to improve the accuracy of the S-phase fraction.'4 The coefficient of variation ranged from 1-8 to 5-2%.
For this study flow cytometric data on tumour cells in the S-(DNA synthesis) and the G2-/ M-(mitosis) phases were added together to give a 'proliferative index.' On the basis of previous experience with many other tumours,'5 indices were classified into three categories corresponding to low (index <9-5%), moderate (9-5-15%), and high proliferative activity (> 15%).
In a second approach, the expression of the proliferation antigen Ki67 was studied. This nuclear antigen is present in cells only within the late G,-, S-, G2-, and M-phases of the cell cycle but not in resting cells. 16 17 Immunohistochemistry was performed on cryostat sections of fresh frozen tumour tissue by using the monoclonal antibody Ki67'6 (Dianova, Hamburg, Germany) in an indirect streptavidin biotin-peroxidase method.
Ki67 immunoreaction was evaluated under light microscopy at 400-fold magnification by two independent observers (AvH, BS). The immunoreaction was graded semiquantitatively on the basis of a score between 1+ and 3+: 1+=low (Fig 1), 2+=moderate (Fig 2) , and 3+ =a high proportion (Fig 3) of Ki67 immunoreactive tumour cells.
Proliferative activity was correlated with the clinical course in seven patients with malignant gastroenteropancreatic neuroendocrine tumours and in one patient with a non-resectable extravisceral tumour. Postoperative follow up ranged from 12 to 28 months. All four patients with benign pancreatic endocrine tumours were probably cured by local resection. Patient 2 was lost to follow up.
Results
Individual results are presented in the Table. DNA FLOW CYTOMETRY In four small intestinal carcinoids (patients 1-4) the proliferative indices had a wide range. In one duodenal carcinoid (patient 1) the proliferative index was 36-2%, corresponding to high proliferative activity. One ileum carcinoid metastatic to the mesentery (patient 2) had an index of 11-4%, corresponding to moderate proliferative activity. Two other ileum carcinoids (patients 3 and 4), however, had indices of 8-8% and 2-9%, respectively, as did the liver metastasis of one (patient 4, index 6-8%), all reflecting low prolif-. ; . erative activity. The serotonin immunoreactive extravisceral neuroendocrine tumour (patient 5) had an index of 5-2%, corresponding to low proliferative activity.
In four endocrine pancreatic tumours with metastases (patients 6-9) indices ranged from 8 7 to 18-3% -that is, from low to high proliferative activity. The liver metastases of two pancreatic tumours had either enhanced (index 18-3% v 9*1%, patient 6) or roughly similar (8-7% v 10-4%, patient 7) proliferative activity compared with their respective primary tumours. The proliferative activity indices of the other four endocrine pancreatic tumours (patients 10-13) had a small range, 4 
Discussion
The growth of gastroenteropancreatic neuroendocrine tumours is as yet largely unstudied. Articles in textbooks'8 19 and other reviews20 emphasise that slow growth and low mitotic rate are typical. In contrast to these empirical descriptions, we found the proliferative activity of the tumours, as determined by two different methods, to be heterogeneous. Although the number oftumours we studied was limited, some trends may be recognised with respect to the tumour's hormonal activity and proliferation. They do, however, require comment.
Comparing gastroenteropancreatic neuroendocrine tumours on the basis of the presence or absence of hormone activity showed that five of six small intestinal carcinoid and pancreatic endocrine tumours with no hormone activity had greater proliferative activity than tumours with hormone activity. We also observed, however, an extravisceral carcinoid tumour without hormone activity that had low proliferative activity, similar to a pancreatic endocrine tumour without hormone activity studied previously.2! Thus, although gastroenteropancreatic neuroendocrine tumours without hormone activity (corresponding to loss of endocrine cell differentiation) tend to have higher proliferative activity than tumours with hormone activity (reflecting persistence of functional differentiation), the individual growth behaviour escapes generalisation.
Comparing these neuroendocrine tumours on the basis of their growth behaviour showed that seven of eight malignant tumours had greater proliferative activity than all five benign tumours. The At first sight, DNA flow cytometry seems to be a more reliable diagnostic test than Ki67 immunohistochemistry for determining proliferative tumour activity by providing numerical data. But, as the essential accuracy of flow cytometric S-phase fraction measurements is dependent on individual laboratory procedures and a low coefficient of variation (<5%), the interpretation of the numerical data obtained should be considered critically.'2 If DNA flow cytometry is not available, immunohistochemistry for the Ki67 defined nuclear proliferation antigen may be an alternative. In our experience subjective scoring of Ki67 immunohistochemistry achieved results comparable with those obtained with DNA flow cytometry by differentiating tumours with low, moderate, and high proliferative activity.
In view of the natural heterogeneity in the growth kinetics of gastroenteropancreatic neuroendocrine tumours, as shown by adequate techniques, the diagnostic value of estimating the proliferative activity of the individual tumour for a rational therapeutic concept should be investigated prospectively. 
